公开(公告)号：US11034769B1

公开(公告)日：2021-06-15

申请号：US17145001

申请日：2021-01-08

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Eiji Inoue ,  Akio Yamada ,  Tomomi Kawakatsu ,  Toshio Imai ,  Maki Deguchi ,  Aki Nakatani

IPC: C07K16/28 ,  A61K39/395 ,  A61P25/28 ,  C12N15/00 ,  C12N15/63 ,  A61K39/00 ,  C12N15/62

Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient.
A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.

公开(公告)号：US11136400B2

公开(公告)日：2021-10-05

申请号：US17145001

申请日：2021-01-08

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Eiji Inoue ,  Akio Yamada ,  Tomomi Kawakatsu ,  Toshio Imai ,  Maki Deguchi ,  Aki Nakatani

IPC: C07K16/28 ,  A61K39/395 ,  A61P25/28 ,  C12N15/00 ,  C12N15/63 ,  A61K39/00 ,  C12N15/62

Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient.
A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.

公开(公告)号：US10947313B2

公开(公告)日：2021-03-16

申请号：US16915412

申请日：2020-06-29

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Eiji Inoue ,  Akio Yamada ,  Tomomi Kawakatsu ,  Toshio Imai ,  Maki Deguchi ,  Aki Nakatani

IPC: C07K16/28 ,  A61K39/395 ,  A61P25/28 ,  A61K39/00

Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient.
A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.